Pheneturide
- N03AX13 (WHO)
- (RS)-N-Carbamoyl-2-phenyl-butanamide
- 90-49-3 N
- 72060
- 65046 Y
- 878CEJ4HGX
- D01190 Y
- DTXSID4020612
- Interactive image
- O=C(N)NC(=O)C(c1ccccc1)CC
- InChI=1S/C11H14N2O2/c1-2-9(10(14)13-11(12)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H3,12,13,14,15) Y
- Key:AJOQSQHYDOFIOX-UHFFFAOYSA-N Y
Pheneturide (INN, BAN) (brand names Benuride, Deturid, Pheneturid, Septotence, Trinuride),[1] also known as phenylethylacetylurea (or ethylphenacemide), is an anticonvulsant of the ureide class.[2][3] Conceptually, it can be formed in the body as a metabolic degradation product from phenobarbital. It is considered to be obsolete[4] and is now seldom used.[5] It is marketed in Europe, including in Poland, Spain and the United Kingdom.[6] Pheneturide has a similar profile of anticonvulsant activity and toxicity relative to phenacemide.[7][8] As such, it is only used in cases of severe epilepsy when other, less-toxic drugs have failed.[8] Pheneturide inhibits the metabolism and thus increases the levels of other anticonvulsants, such as phenytoin.[5][6]
See also
References
- ^ Muller (19 June 1998). European Drug Index: European Drug Registrations, Fourth Edition. CRC Press. pp. 998–. ISBN 978-3-7692-2114-5.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 959–. ISBN 978-1-4757-2085-3.
- ^ Byrne B, Rothchild R (1999). "1H NMR studies of drugs with achiral and chiral lanthanide shift reagents: applications to the anticonvulsant pheneturide". Chirality. 11 (7): 529–35. doi:10.1002/(SICI)1520-636X(1999)11:7<529::AID-CHIR3>3.0.CO;2-K. PMID 10423278.
- ^ Levy RH (2002). Antiepileptic Drugs. Lippincott Williams & Wilkins. pp. 210–. ISBN 978-0-7817-2321-3.
- ^ a b Denham MJ (6 December 2012). The Treatment of Medical Problems in the Elderly. Springer Science & Business Media. pp. 335–. ISBN 978-94-011-6223-4.
- ^ a b Vida J (19 July 2013). Anticonvulsants. Elsevier. pp. 4, 42. ISBN 978-0-323-14395-0.
- ^ deStevens G, Zingel V, Leschke C, Hoeprich PD, Schultz RM, Mehrotra PK, Batra S, Bhaduri AP, Saxena AK, Saxena M, eds. (11 November 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des Recherches Pharmaceutiques. Basel: Birkhäuser. pp. 217–. ISBN 978-3-0348-7161-7. Retrieved 3 September 2016.
- ^ a b Lancaster R (22 October 2013). Pharmacology in Clinical Practice. Elsevier. pp. 222–. ISBN 978-1-4831-9294-9.
- v
- t
- e
modulators
CA inhibitors |
|
---|---|
Others |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e